Literature DB >> 22244664

Current surgical management of ovarian cancer.

John O Schorge1, Eric E Eisenhauer, Dennis S Chi.   

Abstract

Surgical management of ovarian cancer requires excellent judgment and mastery of a wide array of procedures. Involvement of a gynecologic oncologist improves outcomes. Staging of apparent stage I disease is important. Minimally invasive techniques provide advantages. Primary debulking surgery provides the best long-term survival of any strategy in advanced ovarian cancer. Aggressive surgical paradigms have the greatest success. Further cytoreductive surgery may be appropriate. Most relapsed patients require management of bowel obstruction at some point. Palliative intervention can enhance quality of life. Surgical correction may extend survival. For end-stage patients with progressive disease, the treating gynecologic oncologist must manage expectations.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22244664     DOI: 10.1016/j.hoc.2011.10.004

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  11 in total

1.  Gastric metastasis from ovarian cancer presenting as a submucosal tumor: a case report.

Authors:  Eun Young Kim; Cho Hyun Park; Eun Sun Jung; Kyo Young Song
Journal:  J Gastric Cancer       Date:  2014-06-30       Impact factor: 3.720

Review 2.  Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy.

Authors:  Alexandra Lainé; Travis T Sims; Olivia Le Saux; Isabelle Ray-Coquard; Robert L Coleman
Journal:  Curr Oncol Rep       Date:  2021-11-09       Impact factor: 5.075

3.  Impact of robotic surgery on patient flow and resource use intensity in ovarian cancer.

Authors:  Jeremie Abitbol; Beste Kucukyazici; Sonya Brin; Susie Lau; Shannon Salvador; Agnihotram V Ramanakumar; Roy Kessous; Liron Kogan; John D Fletcher; Valerie Pare-Miron; Gilbert Liu; Walter H Gotlieb
Journal:  J Robot Surg       Date:  2022-08-04

4.  Correlation analysis of urine metabolites and clinical staging in patients with ovarian cancer.

Authors:  Ting Jiang; Yunliang Lin; Haiqin Yin; Shanshan Wang; Qinglei Sun; Peihai Zhang; Wenxiang Bi
Journal:  Int J Clin Exp Med       Date:  2015-10-15

5.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer with peritoneal metastasis: a prospective registry study on 41 patients.

Authors:  Melissa Ching Ching Teo; Claramae Shulyn Chia; Cindy Lim; Grace Hwei Ching Tan; Whay Kuang Chia; Khee Chee Soo
Journal:  Pleura Peritoneum       Date:  2017-12-01

Review 6.  Laparoscopy versus laparotomy for FIGO stage I ovarian cancer.

Authors:  Frederico S Falcetta; Theresa A Lawrie; Lídia Rf Medeiros; Maria Ines da Rosa; Maria I Edelweiss; Airton T Stein; Alice Zelmanowicz; Anaelena B Moraes; Roselaine R Zanini; Daniela D Rosa
Journal:  Cochrane Database Syst Rev       Date:  2016-10-13

Review 7.  Lower extremity edema in patients with early ovarian cancer.

Authors:  Myong Cheol Lim; Jeong Seon Lee; Byung Ho Nam; Sang-Soo Seo; Sokbom Kang; Sang-Yoon Park
Journal:  J Ovarian Res       Date:  2014-03-07       Impact factor: 4.234

8.  Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer.

Authors:  Soozana Puvanenthiran; Sharadah Essapen; Ben Haagsma; Izhar Bagwan; Margaret Green; Said Abdullah Khelwatty; Alan Seddon; Helmout Modjtahedi
Journal:  Oncotarget       Date:  2018-04-13

9.  Multivariate Index Assay Is Superior to CA125 and HE4 Testing in Detection of Ovarian Malignancy in African-American Women.

Authors:  Charles Dunton; Rowan G Bullock; Herbert Fritsche
Journal:  Biomark Cancer       Date:  2019-06-14

10.  Quality of Care and Outcomes of Patients With Gynecologic Malignancies Treated at Safety-Net Hospitals.

Authors:  Charlotte R Gamble; Yongmei Huang; Ana I Tergas; Fady Khoury-Collado; June Y Hou; Caryn M St Clair; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  JNCI Cancer Spectr       Date:  2019-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.